The EU approved the formidable drug Tocilizumab, also known as the brand name RoACTEMRA, which is marketed by Roche Pharmaceuticals, at the end of April 2014. As the only FDA approved medication for treating systemic JIA and polyarticular JIA in children, Tocilizumab is well regarded in the United States. Tocilizumab is approved by both the[…]
EU Approves Subcutaneous Tocilizumab for Rheumatoid Arthritis
Anti-Inflammatory, EU Approved 2014, Monoclonal Antibodies / mAb Tags: MethotrexateRheumatoid Arthritis May 14, 2014
Diclofenac Potassium Nets $3 Million in First Quarter of 2013
Anti-Inflammatory, Drug Research & Development API, Patent Expiration 2019 Tags: NSAIDRheumatoid ArthritisWarfarin Jan 02, 2014
Diclofenac Potassium CAS# 15307-81-0, also known as the brand name Zipsor, netted an astounding three million dollars in sales for the first quarter of 2013. Depomed Incorporated, who markets the NSAID, recently reported their better than expected financials regarding this efficacious treatment for arthritis and pain. The patent for Zipsor expires on July 15, 2019,[…]
FDA Approves Self-Administrating Injectable Methotrexate
Anti-Psoriatic, Immunosuppressant Tags: MethotrexatePsoriasisRheumatoid Arthritis Oct 29, 2013
The recent approval by the FDA for the Methotrexate injection was encouraging news for patients with rheumatoid arthritis. The FDA gave a nod to approve Methotrexate as the brand name OTREXUP, which is marketed by Antares Pharma on October 16, 2013. This subcutaneous injectable treatment is quite novel, as it is the very first and[…]
Baricitinib Offers Encouragement to Patients with Rheumatoid Arthritis
Anti-Inflammatory, Drug Research & Development API Tags: PsoriasisRheumatoid Arthritis Jun 26, 2013
Baricitinib has been the source of encouraging news for patients with Rheumatoid Arthritis this week. On June 13, 2013 both Lilly and Incyte revealed at The European League Against Rheumatism, or EULAR, that the new drug Baricitinib is an efficacious treatment option for patients with Rheumatoid Arthritis. As a Janus kinase, or JAK inhibitor, Baricitinib[…]
Breaking News: No Heightened Risk of Shingles for Patients Taking Newer Rheumatoid Arthritis Medications
Anti-Inflammatory, Anti-Psoriatic, Drug Research & Development API, Monoclonal Antibodies / mAb Tags: 331731-18-1AdalimumabEtanerceptHumiraRheumatoid ArthritisRituximab Mar 18, 2013
On March 6, 2013 encouraging results from a study involving rheumatoid arthritis medications were published. This study, available in the March 6 issue of the Journal of the American Medical Association, reassured patients who are taking the newest medications. Results concluded from this particular study revealed that these drugs do not appear to raise the[…]
Etanercept Offers Relief for Patients with Rheumatoid Arthritis
Anti-Inflammatory, Anti-Psoriatic, Drug Research & Development API Tags: Etanerceptplaque psoriasisRheumatoid Arthritis Mar 13, 2012
Etanercept, known by the trade name Enbrel, is indicated for reducing the signs and symptoms of Rheumatoid Arthritis. In addition, etanercept, CAS number 185243-69-0, is effective in reduction of symptoms as related to Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Plaque Psoriasis. Developed by researchers at Immunex, etanercept is marketed as Enbrel by[…]
